For research use only. Not for therapeutic Use.
Tocilizumab (Cat.No:I018310) is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, used to treat various inflammatory conditions. It is approved for rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome associated with chimeric antigen receptor (CAR) T-cell therapy. Tocilizumab effectively reduces inflammation by blocking IL-6 signaling pathways.
| Catalog Number | I018310 |
| CAS Number | 375823-41-9 |
| Purity | ≥95% |
| Reference | [1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70.<br>[2]. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526.<br>[3]. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34.<br>[4]. Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954. |
